Talaris Therapeutics (Talaris Therapeutics) Market Cap : $119.58 Mil (As of Jun. 06, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Talaris Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Talaris Therapeutics's share price for the quarter that ended in Jun. 2023 was $3.04. Talaris Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 42.55 Mil. Therefore, Talaris Therapeutics's market cap for the quarter that ended in Jun. 2023 was $129.35 Mil.

Talaris Therapeutics's quarterly market cap increased from Dec. 2022 ($43.63 Mil) to Mar. 2023 ($78.79 Mil) and increased from Mar. 2023 ($78.79 Mil) to Jun. 2023 ($129.35 Mil).

Talaris Therapeutics's annual market cap increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($625.56 Mil) but then declined from Dec. 2021 ($625.56 Mil) to Dec. 2022 ($43.63 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Talaris Therapeutics's Enterprise Value for Today is $-30.77 Mil.

Talaris Therapeutics Market Cap Historical Data

The historical data trend for Talaris Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talaris Therapeutics Market Cap Chart

Talaris Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Market Cap

625.56

43.63

Talaris Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Market Cap	Get a 7-Day Free Trial										187.09	109.10	43.63	78.79	129.35

Competitive Comparison of Talaris Therapeutics's Market Cap

For the Biotechnology subindustry, Talaris Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talaris Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Talaris Therapeutics's Market Cap falls into.

Talaris Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Talaris Therapeutics's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )	=	Share Price (A: Dec. 2022 )	*	Shares Outstanding (EOP) (A: Dec. 2022 )
	=	$1.02	*	42.7794
	=	$43.63

Talaris Therapeutics's Market Cap for the quarter that ended in Jun. 2023 is calculated as

Market Cap (Q: Jun. 2023 )	=	Share Price (Q: Jun. 2023 )	*	Shares Outstanding (EOP) (Q: Jun. 2023 )
	=	$3.04	*	42.5505
	=	$129.35

Talaris Therapeutics (NAS:TALS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Talaris Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Talaris Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Talaris Therapeutics (Talaris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Talaris Therapeutics Inc (NAS:TALS) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

93 Worcester Street, Wellesley, MA, USA, 02481

Website

https://www.talaristx.com

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Executives

Cariad Chester	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Yung H. Chyung	officer: Chief Medical Officer	C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
W Bradford Middlekauff	officer: CBO, GC and Secretary	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Sandeep Chidambar Kulkarni	director, officer: CEO	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kevin Bruce Johnson	officer: Chief Regulatory Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Ryan F. Robinson	officer: Interim CFO	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Parvinder Thiara	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Susan Dana Jones	officer: Chief Technology Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Suzanne Ildstad	director, 10 percent owner, officer: Chief Scientific Officer	C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481
Scott Requadt	director, officer: See Remarks	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025